Drug Interaction Assessment: Auvelity, Rexulti, and Belsomra Combination
This three-drug combination carries significant CNS polypharmacy risk and should be used with heightened caution, particularly in older adults, but is not absolutely contraindicated if clinically necessary with close monitoring.
Critical Interaction Concerns
CNS Polypharmacy Warning
The most important consideration is that this regimen combines three CNS-active agents (an antidepressant, an antipsychotic, and a hypnotic), which the 2019 AGS Beers Criteria explicitly warns against 1. The guideline states that concurrent use of three or more CNS agents (including antidepressants, antipsychotics, and nonbenzodiazepine receptor agonist hypnotics like Belsomra) significantly increases fall risk and should be avoided in older adults.
Key risks with this combination:
- Increased fall risk (particularly concerning with suvorexant's sedative effects)
- Additive CNS depression (sedation, dizziness, cognitive impairment)
- Psychomotor impairment
Specific Drug-Drug Interactions
Auvelity-Specific Considerations
Bupropion component interactions:
- Bupropion is a CYP2D6 inhibitor (this is actually therapeutic in Auvelity, as it increases dextromethorphan levels) 2
- The FDA label explicitly warns about alcohol intolerance and advises limiting alcohol use 2
- Must screen for other bupropion-containing products to avoid duplication 2
Dextromethorphan component:
- Must screen for other dextromethorphan-containing products (common in OTC cough medications) 2
- The AGS Beers Criteria notes that dextromethorphan/quinidine combinations increase fall risk and drug-drug interaction potential 1
Brexpiprazole (Rexulti) Interactions
Brexpiprazole has minimal interaction potential with this regimen:
- Shows weak inhibitory effects on CYP enzymes (IC50 >13 μmol/L for most) 3
- No clinically significant transporter interactions at therapeutic doses 3
- Not a significant CYP2D6 inhibitor or substrate, so no major pharmacokinetic interaction with Auvelity expected
Suvorexant (Belsomra) Considerations
- Primarily metabolized by CYP3A4, not CYP2D6, so no direct pharmacokinetic interaction with Auvelity's bupropion component
- Main concern is additive CNS depression when combined with other psychotropic medications
- The 10 mg dose is already at bedtime (note: your prescription says "qAM" but this appears to be an error—Belsomra should be taken at bedtime)
Clinical Management Algorithm
1. Patient Risk Stratification
- Age ≥65 years: High-risk population per Beers Criteria—consider alternative strategies
- Fall history: Document baseline fall risk; if present, strongly reconsider this combination
- Renal function: If eGFR 30-59 mL/min, Auvelity dose must be reduced to once daily 2
2. Monitoring Requirements
Before initiating:
- Blood pressure assessment (Auvelity can increase BP) 2
- Screen for bipolar disorder history 2
- Verify no other bupropion or dextromethorphan products
- Assess baseline fall risk and cognitive function
During treatment:
- Monitor blood pressure periodically 2
- Assess for excessive sedation, dizziness, or psychomotor impairment at each visit
- Document any falls or near-falls
- Monitor for suicidal ideation (particularly first 4 weeks) 2
3. Dosing Correction Needed
Your prescription states "Belsomra 10 mg po qAM"—this is incorrect. Suvorexant must be taken at bedtime, not in the morning. The timing should be:
- Auvelity: Once daily in morning (or twice daily after day 3 if tolerated)
- Rexulti: 1 mg in morning
- Belsomra: 10 mg at bedtime (HS), NOT qAM
Common Pitfalls to Avoid
- Do not prescribe Belsomra in the morning—this will cause daytime sedation and significantly increase fall/accident risk
- Do not overlook OTC medications—patients may unknowingly take dextromethorphan-containing cough products
- Do not ignore alcohol use—Auvelity specifically warns about reduced alcohol tolerance 2
- Do not prescribe this combination in patients with seizure disorders—Auvelity is absolutely contraindicated 2
- In older adults, strongly consider whether all three agents are necessary—the Beers Criteria recommendation against 3+ CNS agents is strong 1
When This Combination May Be Justified
Despite the concerns, this combination may be appropriate when:
- Patient has treatment-resistant depression requiring Auvelity
- Psychotic features or severe agitation necessitate Rexulti augmentation
- Significant insomnia impairs functioning and requires Belsomra
- Patient is younger than 65 years with no fall history
- Close monitoring is feasible
The benefit must clearly outweigh the CNS polypharmacy risks, and alternatives should be exhausted first.